Alzheimer’s: ‘Turning point’ in fight against disease as drug found to slow decline by up to 35%

Professor Sir John Hardy (UCL Queen Square Institute of Neurology) said, "The successful outcome of the Eli Lilly’s anti-amyloid antibody donanemab is great news for Alzheimer’s disease and confirms the positive and similar outcome for Eisai’s lecanemab trial late last year".

Read: Evening Standard, More: ITV, Herald, BBC World Service Radio 'Newshour' (from 50 mins, 5 secs), Chemistry World